Summary:
This study is a Phase III, 36-month (total of 10 visits), placebo-controlled, double-blinded clinical trial. The primary objective is to determine whether we can prevent incidence of new
vertebral fracture in postmenopausal women.
Qualified Participants Must:
• be postmenopausal women between the ages of 70 - 90 with osteoporosis